Decompressive Craniectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Decompressive craniectomy (DC) is a neurosurgical procedure in which a large section of the skull — typically 12–15 cm in diameter — is surgically removed to provide space for a swollen brain to expand outward rather than being compressed against the rigid skull vault. The brain has virtually no room to swell within the fixed confines of the cranium; when intracranial pressure (ICP) rises beyond 20 mmHg and cannot be controlled by medical management, the resulting brainstem compression can cause irreversible neurological damage or death. Decompressive craniectomy directly addresses this by eliminating the skull as a pressure-limiting boundary.

The procedure involves a large scalp incision, removal of the bone flap, and incision of the underlying dura mater with insertion of a dural expansion patch — typically made from autologous pericranium or synthetic materials — to create additional volume. The bone flap is either preserved in a bone bank or stored subcutaneously in the patient's abdominal wall to maintain viability for subsequent reimplantation. A second procedure, cranioplasty, is performed 3–12 months later once brain swelling has resolved and the patient is neurologically stable, to restore skull integrity.

Decompressive craniectomy is one of the most dramatic interventions in neurosurgery — it can be lifesaving but carries significant risks and its benefit in specific patient populations has been the subject of major randomised controlled trials including DESTINY II (malignant MCA infarction), RESCUEicp (traumatic brain injury), and DECIMAL. Outcomes vary substantially by underlying cause, patient age, pre-injury neurological status, and speed of surgical intervention. The procedure is performed in level I trauma centres and specialist neurosurgical units worldwide.

Decompressive craniectomy is indicated in conditions causing severe, medically refractory raised intracranial pressure. The most common indication is malignant middle cerebral artery (MCA) infarction — a catastrophic form of ischaemic stroke causing massive hemispheric swelling that peaks at 48–96 hours and carries a mortality of 80% without surgical intervention. The landmark DESTINY II trial demonstrated that DC in patients over 60 years with malignant MCA infarction reduced mortality from 70% to 33%, though many survivors had moderate-to-severe disability.

Traumatic brain injury (TBI) is the second major indication, particularly for acute subdural haematoma, intracerebral contusion with cerebral oedema, or diffuse axonal injury with refractory intracranial hypertension. Other indications include massive cerebellar infarction threatening brainstem compression, large spontaneous intracerebral haemorrhage, fulminant hepatic encephalopathy, and refractory ICP from meningitis, encephalitis, or venous sinus thrombosis.

Ideal candidates for decompressive craniectomy are patients with documented, refractory elevated intracranial pressure (sustained ICP above 20–25 mmHg despite maximum medical management) due to a potentially reversible or survivable cause, with some preserved neurological function suggesting meaningful recovery potential. In malignant MCA infarction, surgery is most beneficial when performed within 48 hours of stroke onset in patients under 60 years. In TBI, candidates include patients with GCS below 8 not explained solely by sedation, CT evidence of mass effect, and age under 65 years without bilateral fixed dilated pupils.

Contraindications include patients in vegetative state prior to the acute event, severe pre-existing co-morbidity with limited life expectancy, bilateral fixed and dilated pupils for more than 30 minutes indicating catastrophic brainstem injury, or patient and family refusal after informed discussion of outcomes. The ethical complexity of DC is significant, as it may convert death into survival with severe disability, an outcome some patients would not want.

Two main surgical configurations are used: unilateral hemicraniectomy and bifrontal decompressive craniectomy. Hemicraniectomy — removal of a large fronto-temporo-parietal bone flap — is the standard approach for unilateral hemispheric pathology such as malignant MCA infarction or unilateral TBI. The bone flap must be large enough (minimum 12 cm diameter) to prevent herniation through the edges, a complication called sinking skin flap syndrome. Bifrontal craniectomy involves bilateral frontal bone removal with a dural expansion patch and is used for bilateral frontal lobe injury or diffuse cerebral swelling.

Medical management of raised ICP prior to considering surgery includes head-of-bed elevation to 30 degrees, osmotherapy with mannitol or hypertonic saline, controlled hypothermia, barbiturate coma, hyperventilation as a temporary measure, and CSF drainage via external ventricular drain. DC is reserved for cases where these measures have failed to control ICP below 20–25 mmHg. Cranioplasty is performed as a planned elective procedure 3–12 months post-DC; autologous bone is preferred, but if not viable, a custom titanium or PEEK implant fabricated from CT data is used. Post-craniectomy care in the neuro-ICU includes ICP monitoring, cerebral perfusion pressure optimisation targeting CPP above 60 mmHg, positioning protocols, and tiered management of refractory intracranial hypertension using osmotherapy, sedation, and temperature control — with craniectomy as a last-tier intervention when all earlier steps have been exhausted.

The most significant benefit of decompressive craniectomy is prevention of death from transtentorial herniation and brainstem compression. In appropriate candidates, the procedure reduces ICP to safe levels within minutes of bone and dural opening, halting the cascade of secondary brain injury. In malignant MCA infarction in patients under 60 years, DC reduces mortality from approximately 80% to 20–30%, with 50–60% of survivors achieving moderate disability enabling assisted or independent self-care.

For TBI, DC allows control of ICP that would otherwise be lethal, and a subset of younger patients with primarily focal injury achieve good functional recovery with intensive rehabilitation. Long-term cognitive and functional recovery following DC continues for 12–24 months and is supported by neuroplasticity, particularly in younger patients. Centres with dedicated neurorehabilitation units achieve significantly better functional outcomes than those without structured post-acute rehabilitation.

Decompressive craniectomy carries substantial risks commensurate with its use in critically ill patients. Early surgical complications include intracranial haematoma at the surgical site (5–10%), wound infection, CSF leak through the scalp (3–7%), and seizures. Paradoxical herniation — where atmospheric pressure causes the brain to herniate inward through the bone defect when the patient is upright — is a recognised complication particularly in the weeks following surgery when ICP normalises.

Long-term risks relate to the underlying brain injury and include persistent vegetative state, severe cognitive impairment, hemiplegia, aphasia, and epilepsy. The risk of the patient surviving with severe disability rather than dying must be explicitly discussed with families before surgery. Cranioplasty carries its own risks including haematoma (3–5%), infection requiring implant removal (5–8%), and resorption of autologous bone (15–25%).

Following decompressive craniectomy, patients are managed in the neurological ICU with continuous ICP monitoring, sedation protocols, careful fluid management, and seizure prophylaxis. The average ICU stay is 2–3 weeks, followed by a step-down neurological ward admission. Formal neurorehabilitation begins as soon as the patient's systemic condition permits — typically within 1–2 weeks — encompassing physiotherapy, occupational therapy, speech and language therapy, and neuropsychology.

Cranioplasty is planned at 3–12 months post-DC when CT imaging confirms brain swelling has resolved. Patients must protect the unprotected brain region from trauma during the interim period — helmets are prescribed for mobile patients. Regular follow-up CT or MRI at 3-month intervals monitors for hydrocephalus (occurring in 20–35% of DC patients), which may require ventriculoperitoneal shunting. Long-term epilepsy monitoring and anticonvulsant management are standard components of follow-up care.

Decompressive craniectomy is a high-cost intervention, reflecting its technical complexity, ICU intensity, and required follow-up. In the United States, the combined cost of emergency DC, ICU care, and hospitalisation typically ranges from USD 80,000 to USD 250,000. The subsequent cranioplasty adds USD 20,000–60,000. Without comprehensive insurance, these costs are catastrophic. In the United Kingdom, DC is funded through the NHS for eligible patients, but non-residents face significant costs in private settings.

For patients requiring elective cranioplasty or neurosurgical procedures, India and Thailand offer neurosurgical expertise at a fraction of Western costs. Major Indian neurosurgical centres perform complex cranial procedures including cranioplasty at total costs of USD 4,000–12,000 — a saving of 60–80% versus the US. Emergency DC must always be performed at the closest appropriately equipped neurosurgical centre regardless of location; medical tourism is relevant only for subsequent elective procedures.

Medical management of raised ICP is always attempted before surgical decompression and may be sufficient in less severe cases. This includes osmotherapy with mannitol or hypertonic saline, barbiturate coma to reduce cerebral metabolic demand, controlled therapeutic hypothermia, and external ventricular drainage to remove CSF and directly reduce ICP. Mechanical hyperventilation temporarily reduces ICP by causing cerebral vasoconstriction but is reserved as a bridge measure only.

For ischaemic stroke, endovascular thrombectomy (mechanical clot removal) is the primary treatment within 6–24 hours of onset and may prevent malignant infarction by restoring perfusion before massive oedema develops. Intravenous thrombolysis with alteplase or tenecteplase is indicated within 4.5 hours if no haemorrhage is confirmed on CT. These reperfusion strategies are the preferred alternatives to DC and should be pursued first wherever time and anatomy permit. DC remains the intervention of last resort for patients in whom these alternatives have failed or are not applicable.